TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21159499
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg) after 30 days
Study: 17077374
Drug: Usual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual and customary care (n = 116; ranging from no treatment after concluding formal rehabilitation to pharmacologic or physiotherapeutic interventions)
Study: 12798886
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg, s.c. injection)
Study: 12798886
Drug: Fulvestrant (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (50 mg, 125 mg, or 250 mg, i.m. injection)
Study: 3875451
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pirazolac 3-times daily for 7 days
Study: 3875451
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac sodium 3-times daily for 7 days
Study: 28940213
Drug: Habit reversal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit reversal treatment (HR) + mometasone furoate (potent steroid)
Study: 28940213
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (potent steroid) alone
Study: 24071762
Drug: Pentaerithrityl tetranitrate
Normalized name: Pentaerithrityl tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerithrityl tetranitrate (PETN) 80 mg b.i.d.
Study: 20064822
Drug: RAAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAAS inhibitors (Group 2)
Study: 20064822
Drug: RAAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAAS inhibitors vs Control
Study: 19018483
Drug: Terlipressin in
Normalized name: terlipressin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin in combination with albumin
Study: 12552210
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine + 1 microg neostigmine
Study: 12552210
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine + 2.5 microg neostigmine
Study: 12552210
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine + 5 microg neostigmine
Study: 8681637
Drug: LPS (lipopolysaccharide)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (lipopolysaccharide) inhalation
Study: 8681637
Drug: CDE (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDE (corn dust extract) inhalation
Study: 1869725
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of methylprednisolone
Study: 6857251
Drug: Control animals
Normalized name: animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control animals (dissociated drug histories)
Study: 27014997
Drug: Secukinumab (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (IV 10 mg/kg at weeks 0, 2, 4 followed by subcutaneous 150 mg or 75 mg)
Study: 27014997
Drug: Secukinumab (IV→150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (IV→150 mg)
Study: 27014997
Drug: Secukinumab (IV→75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (IV→75 mg)
Study: 18629732
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation intervention consisting of education and psychological support, with or without pharmacological therapy, associated with follow-up phone calls
Study: 15870599
Drug: Masking in
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masking in medical treatments
Study: 1091665
Drug: Previous medication
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous medication
Study: 22648444
Drug: Active low-level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-level light therapy (LLLT)
Study: 12739312
Drug: Triptans (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptans (acute migraine pharmacotherapy)
Study: 12739312
Drug: Preventive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive therapy
Study: 8281563
Drug: Low-fluoride solution
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluoride solution (0.5% F) applied 10 times a year
Study: 8281563
Drug: Standard topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard topical amine fluoride solution (1% F)
Study: 26499921
Drug: E10030 (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: E10030 (0.03 mg) in combination with ranibizumab (0.5 mg)
Study: 26499921
Drug: E10030 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg)
Study: 22900702
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acid (400 mg, equivalent to 2 cups of coffee)
Study: 17064525
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao 500 mg three times daily for 5 days
Study: 3799505
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of elemental calcium for 8 weeks
Study: 29426006
Drug: Ayurvedic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic treatment (multi-modal)
Study: 17765316
Drug: p38-MAPK inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p38-MAPK inhibitors
Study: 12052577
Drug: Injectable diacetylmorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable diacetylmorphine (pharmaceutical heroin)
Study: 12052577
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) application of heroin under medical supervision
Study: 18230250
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination drugs (FDCs)
Study: 18230250
Drug: Loose drugs
Normalized name: Goose
DrugBank: Goose (DB10874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose drugs
Study: 2484663
Drug: Pirbuterol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 0.4 mg
Study: 1346562
Drug: Pirbuterol 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 0.8 mg
Study: 1346562
Drug: Pirbuterol 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol 1.2 mg
Study: 6437131
Drug: Tocainide HCl
Normalized name: tocainide HCl
DrugBank: Tocainide (DB01056)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tocainide HCl (900 mg daily)
Study: 24488498
Drug: Low-dose enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose enteric-coated aspirin tablets (100 mg/day for 2 years)
Study: 20179259
Drug: Pitavastatin 1
Normalized name: PITAVASTATIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 1 mg once daily
Study: 15675981
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rHuEPO therapy)
Study: 2266990
Drug: Mazindol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (3 mg/d)
Study: 6106828
Drug: sulphinpyrazone (SPZ)
Normalized name: Sulphinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulphinpyrazone (SPZ) 200 mg orally
Study: 28317828
Drug: magnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: magnetic therapy for 5 min №10 in maxillary and mandibular areas
Study: 16330466
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ramipril 5 mg/day + candesartan 8 mg/day)
Study: 16330466
Drug: Ramipril alone
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril alone (10 mg/day)
Study: 16330466
Drug: Candesartan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan alone (16 mg/day)
Study: 8225636
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg b.i.d. for 5 days
Study: 8225636
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg b.i.d. for 10 days
Study: 3081928
Drug: Oxazepam 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 1.2 mg/kg
Study: 30230257
Drug: Old drug
Normalized name: Oldenlandia diffusa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old drug product (DP)
Study: 30230257
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug product (DP)
Study: 30230257
Drug: Upper arm
Normalized name: A And D Medical UA-651 Upper Arm BPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper arm injection site
Study: 30230257
Drug: Thigh injection
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh injection site
Study: 30230257
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of emicizumab
Study: 25004335
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral estradiol per day
Study: 25004335
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg venlafaxine per day
Study: 19826112
Drug: 31 oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31 oncology drugs approved without a randomized trial
Study: 19826112
Drug: Gefitinib (EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (EGFR inhibitor)
Study: 19826112
Drug: 31 oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31 oncology drugs
Study: 19826112
Drug: 19 of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 of the 31 drugs
Study: 12690666
Drug: Dopaminergic agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic agonists
Study: 12690666
Drug: Catechol‐O‐methyl transferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catechol‐O‐methyl transferase inhibitors
Study: 9522658
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg
Study: 9522658
Drug: Methylprednisolone (MPPT)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MPPT) 30 mg/kg
Study: 2570086
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol decanoate (1.5 cc or 75 mg)
Study: 2570086
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (1 cc or 25 mg)
Study: 183591
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of prednisone on alternate days
Study: 183591
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets on alternate days
Study: 183591
Drug: Prednisone maintenance
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone maintenance dosage after 2 years
Study: 31116017
Drug: Audio-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-based cognitive behavioral therapy
Study: 29901860
Drug: BFF MDI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BFF MDI 320/10 μg
Study: 29901860
Drug: BUD/FORM DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FORM DPI 320/9-μg delivered dose
Study: 28598402
Drug: Carbohydrate mouth
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate mouth rinsing (CHO: 1.6 g/25 mL)
Study: 28598402
Drug: Caffeine mouth
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine mouth rinsing (CAF: 67 mg/25 mL)
Study: 28598402
Drug: Guarana mouth
Normalized name: GUARANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guarana mouth rinsing (GUA: 0.4 g/25 mL)
Study: 25740807
Drug: Large-diameter deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-diameter deep anterior lamellar keratoplasty (L-DALK)
Study: 10223231
Drug: 5-FU 2600
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2600 mg/m2 with LV 100 mg/m2 administered via a portable infusion pump over 24 hours once a week for 5 weeks
Study: 2695558
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (vascular medications)
Study: 343787
Drug: Vincamine containing
Normalized name: vincamine
DrugBank: Vincamine (DB13374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincamine containing formulation (Pervincamin forte retard or Pervincamin ampoules)
Study: 31504690
Drug: High water
Normalized name: Dimethicone 1.5 g in 75 mL TOPICAL CREAM [SONATURAL HIGH WATER DRAW SUPER HYDRA BALM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High water intake (2.5 L/d)
Study: 31504690
Drug: Low water
Normalized name: Acetonitrile Low Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low water intake (0.5 L/d)
Study: 21256094
Drug: Levamisole administered
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole administered as a liniment
Study: 16392147
Drug: 1,450-nm diode
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,450-nm diode laser treatment with cryogen cooling spray, 4, 8, or 12 J/cm2, 3 treatments at 6-week intervals
Study: 12685794
Drug: Conical transmucosal
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical transmucosal implants (Nobel Biocare AB), 3.75 mm large and at least 9 mm long, immediately loaded with an implant‐retained overdenture.
Study: 12685794
Drug: Standard Brånemark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Brånemark implants (MK II; Nobel Biocare AB), 3.75 mm large and at least 10 mm long, immediately loaded with an implant‐retained overdenture.
Study: 9859076
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg/24 h in a single daily dose for 12 days)
Study: 9859076
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g/8 h per os) plus netilmicin (4 mg/kg/24 h in a single intramuscular daily dose for 5 days)
Study: 9859076
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus netilmicin
Study: 9859076
Drug: Cefixime and
Normalized name: cefixime and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime and Amoxicillin plus netilmicin
Study: 7631301
Drug: Hemovasal (glycosaminoglycan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemovasal (glycosaminoglycan) administered in 3 different i.m. doses as single injections
Study: 7631301
Drug: Hemovasal (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemovasal (300 mg daily oral dose for one week)
Study: 752851
Drug: Vincristine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine, cyclophosphamide, methotrexate, and 5-fluorouracil after conventional curative treatment
Study: 21336855
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (intraperitoneal cisplatin, postoperative intravenous cisplatin, 5-fluorouracil, and daily oral FU (UFT) for 12 months)
Study: 9783935
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg tamsulosin
Study: 2974263
Drug: procaterol 0.05
Normalized name: procaterol 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: procaterol 0.05 mg twice daily for 2 wk followed by 0.10 mg twice daily for 10 wk
Study: 2974263
Drug: albuterol 2
Normalized name: albuterol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol 2 mg three times a day for 2 wk followed by 4 mg three times a day for 10 wk
Study: 2974263
Drug: albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol
Study: 2974263
Drug: procaterol and
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: procaterol and albuterol
Study: 30530121
Drug: Oral β‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral β‐blocker therapy
Study: 29534639
Drug: Sunitinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib as an adjunct to standard therapy (leucovorin, 5-fluorouracil, and irinotecan)
Study: 29534639
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an adjunct to standard therapy (leucovorin, 5-fluorouracil, and irinotecan)
Study: 29534639
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (leucovorin, 5-fluorouracil, and irinotecan)
Study: 26467679
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion (OHP) activities
Study: 22057424
Drug: β-glucan-enriched beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-glucan-enriched beverage (3 g barley β-glucan)
Study: 22057424
Drug: Fruit-based beverage
Normalized name: RESOURCE FRUIT BEVERAGE LIQUID (ORANGE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit-based beverage (2.5 g dietary fibre)
Study: 17374316
Drug: Efalizumab 1
Normalized name: efalizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1 mg/kg weekly for 12 weeks
Study: 7598055
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with energy density of 1.67, 2.93, 4.18, or 6.28 kJ/g fed ad libitum three, four, or five times per day
Study: 2220978
Drug: 200,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU of oral vitamin A
Study: 619324
Drug: Combination chemotherapeutic
Normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapeutic agents (ACFUME, ACFUCY)
Study: 30220280
Drug: Insulin caliper
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin caliper for blood glucose control
Study: 30220280
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (paper-based insulin dose modification scheme)
Study: 27217097
Drug: High-purity plasma-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-purity plasma-derived factor X concentrate (pdFX) administered preoperatively to raise FX:C to 70-90 IU dL(‐1) and postoperatively to maintain levels >50 IU dL(‐1) until no longer at risk of bleeding due to surgery.
Study: 22112969
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 day 1) and prednisone (5 mg orally twice daily every 21 days) plus AT-101 (40 mg twice daily on days 1-3)
Study: 22112969
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 day 1) and prednisone (5 mg orally twice daily every 21 days) plus placebo
Study: 20940688
Drug: Information on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information on anxiolytic technique, local anesthesia, and treatment of perioperative pain
Study: 17438342
Drug: Eclectic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eclectic treatment
Study: 16678648
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 10 mg/d
Study: 16678648
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 20 mg/d
Study: 1517643
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) 100 mg by mouth twice daily
Study: 1517643
Drug: Buprenorphine (Bu)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine (Bu) 0.2 mg sublingually twice daily
Study: 1517643
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (PHT 50 mg PO + Bu 0.1 mg SL twice daily)
Study: 6149671
Drug: Prenalterol (100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (100‐200 mg daily)
Study: 6149671
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment with diuretics
Study: 6149671
Drug: Control periods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control periods / intensified conventional treatment
Study: 30412325
Drug: Baseline viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline viral load cutpoint of 800,000 IU/mL
Study: 28436380
Drug: Entecavir-adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Entecavir-adefovir dipivoxil (ETV-ADV) combination therapy
Study: 28091491
Drug: Standard pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmaceutical treatment for IBS (myotropic anti‐spasmodics and lactulose)
Study: 22281004
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg for the first two weeks, 10 mg for the last two weeks)
Study: 20133263
Drug: Albumin-bound paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin-bound paclitaxel weekly for 12 weeks followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) every 3 weeks for 4 cycles
Study: 18751500
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation containing 400 mg dexibuprofen
Study: 18751500
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation containing 400 mg dexibuprofen
Study: 10372564
Drug: Gabapentin (600,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600, 1200, or 2400 mg/day)
Study: 8908676
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist leuprolide depot for 24 weeks